Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Allogeneic hematopoietic cell transplantation in TP53-mutated Acute Myeloid Leukemia patients with active disease: A study from the global committee and the acute leukemia working party of the EBMT

View Full Paper
Ask AI
Bookmark
Share

Authors

NKNicolaus KrögerIBIgor Wolfgang BlauJPJakob Passweg

Discussion

Loading...

Member takes

Overview

Analysis reveals modest survival benefits and high relapse incidence in TP53-mutated AML patients, suggesting need for novel treatment strategies.

Key Points

  • To evaluate the outcomes of allogeneic hematopoietic cell transplantation in patients with TP53-mutated acute myeloid leukemia with active disease.
  • Data collected from EBMT registry across 83 centers.
  • Included 183 adult patients with TP53-mutated AML who underwent allo-HCT.
  • Outcomes assessed included overall survival, leukemia-free survival, and graft-versus-host disease.
  • Overall survival at 2 years was 20.5%, with a relapse incidence of 53.2%.
  • Graft-versus-host disease occurred in 31.8% of patients, with chronic GVHD in 17%.
  • Novel treatment strategies needed to improve outcomes in this high-risk population.

Cite This Study

Kröger et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d475https://doi.org/10.1182/blood-2025-2523
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study2025 · 1 citations
  2. 2Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation2026
  3. 3Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes2025
  4. 4Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis2025
  5. 5Impact of germline and somatic TP53 mutations on allogeneic HSCT outcomes in hematologic malignancies2025